What is Gallant?
Gallant is pioneering a new frontier in animal health by developing off-the-shelf stem cell therapies designed to address the root causes of diseases in pets. Moving beyond traditional symptom management, the company's pipeline focuses on restoring health at a fundamental level. The firm is led by recognized experts in veterinary regenerative medicine, bringing extensive experience in development, manufacturing, and commercialization to make advanced regenerative treatments accessible for companion animals.
How much funding has Gallant raised?
Gallant has raised a total of $28.2M across 2 funding rounds:
Other Financing Round
$18M
Private Equity
$10.2M
Other Financing Round (2025): $18M with participation from Digitalis Ventures and NovaQuest Capital Management
Private Equity (2025): $10.2M, investors not publicly disclosed
Key Investors in Gallant
Digitalis Ventures
Digitalis Ventures engineers solutions to unmet needs in health by leveraging deep technical, financial, and domain expertise. The company invests in biotechnology and technology-enabled solutions aimed at improving human and animal health while reducing costs.
NovaQuest Capital Management
NovaQuest Capital Management is a premier biopharma and life sciences investment firm that pioneered a PRODUCT FINANCE investment solution. They provide at-risk, nondilutive funding to advance pivotal clinical trials, launch new brands, license products, and acquire accretive products or companies.
What's next for Gallant?
With this substantial enterprise-level funding, Gallant is poised to accelerate its research and development efforts, scale its manufacturing capabilities, and expand its commercial reach. The strategic investment signals strong confidence from backers in Gallant's innovative approach to veterinary medicine, suggesting a trajectory towards becoming a leader in the regenerative animal health market. Future growth will likely involve further clinical validation, regulatory approvals, and market penetration to bring their novel therapies to a wider pet population.
See full Gallant company page
